Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma?data from the Czech registry

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F12%3A%230000233" target="_blank" >RIV/00064190:_____/12:#0000233 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/12:00059259 RIV/00216208:11110/12:12165 RIV/61989592:15110/12:33141418 RIV/00209805:_____/12:#0000360 RIV/00064190:_____/12:#0000309

Výsledek na webu

<a href="http://dx.doi.org/10.1093/annonc/mdr065" target="_blank" >http://dx.doi.org/10.1093/annonc/mdr065</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1093/annonc/mdr065" target="_blank" >10.1093/annonc/mdr065</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma?data from the Czech registry

Popis výsledku v původním jazyce

Background: Sequential therapy with tyrosine kinase inhibitors (TKIs), sunitinib and sorafenib, is a common treatment choice for patients with advanced/metastatic renal cell carcinoma (mRCC) despite lack of randomised trials. The aim of this retrospective registry-based study was to analyse the outcomes of RCC patients treated with sunitinib? sorafenib or sorafenib?sunitinib sequence. Patients and methods: The Czech database containing information on patients treated for mRCC using targeted agents was used as a source of data for retrospective analysis. There were 138 patients treated with sunitinib? sorafenib sequence and 122 patients treated with sorafenib?sunitinib sequence. Results: Progression-free survival (PFS) was 17.7 months for patients treated with sunitinib?sorafenib sequence and 18.8 months for those receiving sorafenib followed by sunitinib (P = 0.47). Overall survival (OS) at 1 year was 83% [95% confidence interval (CI) 77% to 90%] for patients treated with sunitinib?sor

Název v anglickém jazyce

Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma?data from the Czech registry

Popis výsledku anglicky

Background: Sequential therapy with tyrosine kinase inhibitors (TKIs), sunitinib and sorafenib, is a common treatment choice for patients with advanced/metastatic renal cell carcinoma (mRCC) despite lack of randomised trials. The aim of this retrospective registry-based study was to analyse the outcomes of RCC patients treated with sunitinib? sorafenib or sorafenib?sunitinib sequence. Patients and methods: The Czech database containing information on patients treated for mRCC using targeted agents was used as a source of data for retrospective analysis. There were 138 patients treated with sunitinib? sorafenib sequence and 122 patients treated with sorafenib?sunitinib sequence. Results: Progression-free survival (PFS) was 17.7 months for patients treated with sunitinib?sorafenib sequence and 18.8 months for those receiving sorafenib followed by sunitinib (P = 0.47). Overall survival (OS) at 1 year was 83% [95% confidence interval (CI) 77% to 90%] for patients treated with sunitinib?sor

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

ANNALS OF ONCOLOGY

ISSN

0923-7534

e-ISSN

—

Svazek periodika

23

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

395-401

Kód UT WoS článku

000299744400018

EID výsledku v databázi Scopus

—